



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 9/14</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/25190</b>  <b>(43) International Publication Date:</b> 23 December 1993 (23.12.93)
<b>(21) International Application Number:</b> PCT/US93/05082 <b>(22) International Filing Date:</b> 1 June 1993 (01.06.93)  <b>(30) Priority data:</b> 897,193                      10 June 1992 (10.06.92)                      US  <b>(71) Applicant:</b> STERLING WINTHROP INC. [US/US]; 90 Park Avenue, New York, NY 10016 (US).  <b>(72) Inventors:</b> LIVERSIDGE, Gary, G. ; 258 Colwyn Terrace, West Chester, PA 19380 (US). CONZENTINO, Philip ; 1001 Nicholas Drive, West Chester, PA 19380 (US). CUNDY, Kenneth, C. ; 3802 Naughton Avenue, Bel- mont, CA 94002 (US). SARPOTDAR, Pramod, P. ; 5 Knollbrook Circle, Malvern, PA 19355 (US).		<b>(74) Agent:</b> DAVIS, William, J.; 343 State Street, Rochester, NY 14650-2201 (US).  <b>(81) Designated States:</b> AU, CA, HU, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SURFACE MODIFIED NSAID NANOPARTICLES  <b>(57) Abstract</b>  Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit reduced gastric irritation following oral administration and/or hastened onset of action.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## SURFACE MODIFIED NSAID NANOPARTICLES

## BACKGROUND OF INVENTION

5

Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used and therapeutically effective groups of drugs. However, gastric irritation problems constitute the most frequently recognized adverse side effect following oral administration of NSAIDs. Such side effects are well recognized and must be weighed against the clinical efficacy of the drugs.

A great amount of research has been undertaken in an attempt to understand the underlying mechanism responsible for these effects. For example, Cioli et al, Tox. and Appl. Pharm., 50, 283-289 (1979) suggest that gastrointestinal lesions in laboratory animals resulting from the oral administration of acidic NSAIDs may depend on two different mechanisms: a local action exerted by contact with the gastric mucosa and a generalized/centrally mediated (systemic) action, taking place following oral administration.

More recently, Price et al, Drugs 40 (Suppl. 5):1-11, 1990, suggest that NSAID-induced gastric damage occurs as a result of NSAID-mediated direct and indirect acidic damage followed almost simultaneously by the deleterious systemic effect of prostaglandin inhibition.

A variety of strategies have been used in the management of NSAID-induced gastric damage. These include:

- 1) the development and use of NSAIDs with less toxic potential; 2) the reduction or elimination of the agent that actually causes the injury; and 3) the enhancement of the mucosal defense. However, these approaches have not proven entirely successful.

For example, the most effective means of preventing gastric damage, i.e., by eliminating the primary aetiological

agent is rarely feasible with NSAIDs inasmuch as patients with severe inflammatory disease are rarely able to cease using these drugs. Although selection of less toxic NSAIDs should prove useful, the only practical solution, at present, is to treat the NSAID induced gastric damage. Misoprostol (a methylated prostaglandin E<sub>1</sub>) has been approved by the FDA for use in preventing NSAID gastropathy. However, Misoprostol is expensive, must be administered multiple times daily and can cause unacceptable side effects.

Thus it would be highly desirable to provide NSAID formulations that can exhibit a reduction in gastric irritation. Moreover, it would be desirable to provide NSAID formulations exhibiting hastened onset of action.

15

## SUMMARY OF THE INVENTION

We have discovered that pharmaceutical compositions containing surface modified NSAID nanoparticles exhibit reduced gastric irritation following oral administration and/or more rapid onset of action.

More particularly, in accordance with this invention, there are provided particles consisting essentially of an NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an average particle size of less than about 400 nm.

This invention further provides a pharmaceutical composition comprising the above-described particles and a pharmaceutically acceptable carrier.

In another embodiment of the invention, there is provided a method of treating a mammal comprising administering to the mammal the above-described pharmaceutical composition.

In yet another embodiment of the invention, there is provided a method of preparing the above-described particles comprising the steps of dispersing an NSAID in a liquid dispersion medium and wet grinding the NSAID in the

presence of rigid grinding media, wherein the pH of said medium is maintained within the range of from 2 to 6.

In further embodiments of the invention, there are provided methods of reducing gastric irritation and/or  
5 hastening the onset of action which include administering the above-described pharmaceutical composition to a mammal.

It is an advantageous feature of this invention that pharmaceutical compositions containing NSAIDs are provided which exhibit reduced gastric irritation following  
10 oral administration.

It is another advantageous feature of this invention that pharmaceutical compositions are provided exhibiting hastened onset of action.

Other advantageous features will become readily  
15 apparent upon reference to the following description of preferred embodiments.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 This invention is based partly on the discovery that surface modified nanoparticles comprising an NSAID, e.g., naproxen, demonstrate reduced gastric irritation and/or a more rapid onset of action following oral administration. While the invention is described herein primarily in  
25 connection with its preferred class of drugs, i.e., NSAIDs, it is also useful in conjunction with other classes of drug substances, e.g., antibiotics, quinolones, antilipemics and roentgenographics.

30 The particles of this invention comprise an NSAID. The NSAID exists as a discrete, crystalline phase. The crystalline phase differs from an amorphous or non-crystalline phase which results from conventional solvent  
35 precipitation techniques, such as described in U.S. Patent 4,826,689. The NSAID can be present in one or more suitable

crystalline phases.

The invention can be practiced with a wide variety of NSAIDs. However, the NSAID must be poorly soluble and dispersible in at least one liquid medium. By "poorly  
5 soluble" it is meant that the NSAID has a solubility in the liquid dispersion medium, e.g., water, of less than about 10 mg/ml, and preferably of less than about 1 mg/ml at processing temperature, e.g., room temperature. The preferred liquid dispersion medium is water. However, the  
10 invention can be practiced with other liquid media in which the NSAID is poorly soluble and dispersible including, for example, aqueous salt solutions, safflower oil and solvents such as ethanol, t-butanol, hexane and glycol. The pH of the aqueous dispersion media can be adjusted by techniques known  
15 in the art.

The NSAIDs useful in the practice of this invention can be selected from suitable acidic and nonacidic compounds. Suitable acidic compounds include carboxylic acids and enolic acids. Suitable nonacidic compounds include, for example,  
20 nabumetone, tiaramide, proquazone, bufexamac, flumizole, epirazole, tinoridine, timegadine and dapsone.

Suitable carboxylic acid NSAIDs include, for example, salicylic acids and esters thereof, such as aspirin, diflunisal, benorylate and fosfosal; acetic acids, including  
25 phenylacetic acids such as diclofenac, alclofenac and fenclofenac, and carbo- and heterocyclic acetic acids such as etodolac, indomethacin, sulindac, tolmetin, fentiazac and tilomisole; propionic acids, such as carprofen, fenbufen, flurbiprofen, ketoprofen, oxaprozin, suprofen, tiaprofenic  
30 acid, ibuprofen, naproxen, fenoprofen, indoprofen, pirprofen; and fenamic acids, such as flufenamic, mefenamic, meclofenamic and niflumic.

Suitable enolic acid NSAIDs include, for example, pyrazolones such as oxyphenbutazone, phenylbutazone, apazone  
35 and feprazone, and oxicams such as piroxicam, sudoxicam, isoxicam and tenoxicam.

The above-described NSAIDs are known compounds and can be prepared by techniques known in the art.

In particularly preferred embodiments of the invention, the NSAID is naproxen, indomethacin or ibuprofen.

5           The particles of this invention contain an NSAID as described above having a surface modifier adsorbed on the surface thereof. Useful surface modifiers are believed to include those which physically adhere to the surface of the NSAID but do not chemically bond to the NSAID.

10           Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic  
15 surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters,  
20 polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens<sup>TM</sup>, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide,  
25 phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine,  
30 polyvinyl alcohol (PVA), and polyvinylpyrrolidone (PVP). Most of these excipients are described in detail in the *Handbook of Pharmaceutical Excipients*, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical  
35 Press, 1986. The surface modifiers are commercially available and/or can be prepared by techniques known in the

art. Two or more surface modifiers can be used in combination.

Particularly preferred surface modifiers include polyvinylpyrrolidone, tyloxapol, polaxomers, such as Pluronic™ F68 and F108, which are block copolymers of ethylene oxide and propylene oxide available from BASF, and poloxamines, such as Tetronic™ 908 (T908), which is a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine available from BASF, dextran, lecithin, Aerosol OT™, which is a dioctyl ester of sodium sulfosuccinic acid, available from American Cyanamid, Duponol™ P, which is a sodium lauryl sulfate, available from DuPont, Triton™ X-200, which is an alkyl aryl polyether sulfonate, available from Rohm and Haas, Tween 20 and Tween 80, which are polyoxyethylene sorbitan fatty acid esters, available from ICI Speciality Chemicals, Carbowax™ 3550 and 934, which are polyethylene glycols available from Union Carbide, Crodesta™ F-110, which is a mixture of sucrose stearate and sucrose distearate, available from Croda Inc., Crodesta SL-40, which is available from Croda, Inc., and SA90HCO, which is  $C_{18}H_{37}-CH_2(CON(CH_3)CH_2(CHOH)_4CH_2OH)_2$ . Surface modifiers which have been found to be particularly useful include polyvinylpyrrolidone, Pluronic F-68, and lecithin.

The surface modifier is adsorbed on the surface of the NSAID in an amount sufficient to maintain an effective average particle size of less than about 400 nm. The surface modifier does not chemically react with the NSAID or itself. Furthermore, the individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.

As used herein, particle size refers to a number average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation. By "an

effective average particle size of less than about 400 nm" it is meant that at least 90% of the particles have a number average particle size of less than about 400 nm when measured by the above-noted techniques. In preferred embodiments of the invention, the effective average particle size is less than about 300 nm. With reference to the effective average particle size, it is preferred that at least 95% and, more preferably, at least 99% of the particles have a particle size of less than the effective average, e.g., 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm.

The particles of this invention can be prepared in a method comprising the steps of dispersing an NSAID in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the NSAID to an effective average particle size of less than about 400 nm. The particles can be reduced in size in the presence of a surface modifier. Alternatively, the particles can be contacted with a surface modifier after attrition.

A general procedure for preparing the particles of this invention is set forth below. The NSAID selected is obtained commercially and/or prepared by techniques known in the art in a conventional coarse form. It is preferred, but not essential, that the particle size of the coarse NSAID selected be less than about 100  $\mu\text{m}$  as determined by sieve analysis. If the coarse particle size of the NSAID is greater than about 100  $\mu\text{m}$ , then it is preferred that the particles of the NSAID be reduced in size to less than 100  $\mu\text{m}$  using a conventional milling method such as airjet or fragmentation milling.

The coarse NSAID selected can then be added to a liquid medium in which it is essentially insoluble to form a premix. The concentration of the NSAID in the liquid medium can vary from about 0.1 - 60%, and preferably is from 5 - 30% (w/w). It is preferred, but not essential, that the surface modifier be present in the premix. The concentration of the

surface modifier can vary from about 0.1 to about 90%, and preferably is 1 - 75%, more preferably 20-60%, by weight based on the total combined weight of the drug substance and surface modifier. The apparent viscosity of the premix  
5 suspension is preferably less than about 1000 centipoise.

The premix can be used directly by subjecting it to mechanical means to reduce the average particle size in the dispersion to less than 400 nm. It is preferred that the premix be used directly when a ball mill is used for  
10 attrition. Alternatively, the NSAID and, optionally, the surface modifier, can be dispersed in the liquid medium using suitable agitation, e.g., a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It  
15 is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.

The mechanical means applied to reduce the particle size of the NSAID conveniently can take the form of a  
20 dispersion mill. Suitable dispersion mills include a ball mill, an attritor mill, a vibratory mill, a planetary mill, media mills such as a sand mill and a bead mill. A media mill is preferred due to the relatively shorter milling time required to provide the intended result, i.e., the desired  
25 reduction in particle size. For media milling, the apparent viscosity of the premix preferably is from about 100 to about 1000 centipoise. For ball milling, the apparent viscosity of the premix preferably is from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance  
30 between efficient particle fragmentation and media erosion.

The grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than about 3 mm and, more preferably, less than about 1 mm. Such media  
35 desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling

equipment. The selection of material for the grinding media is not believed to be critical. However, zirconium oxide, such as 95% ZrO stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of pharmaceutical compositions. Further, other media, such as stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium, are expected to be useful.

Preferred media have a density greater than about 2.5 g/cm<sup>3</sup>.

10           The attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected. For ball mills, processing times of up to five days or longer may be required. On the other hand, processing times of less than 1 day (residence times of one  
15 minute up to several hours) have provided the desired results using a high shear media mill.

          The particles must be reduced in size at a temperature which does not significantly degrade the NSAID. Processing temperatures of less than about 30 - 40°C are  
20 ordinarily preferred. If desired, the processing equipment can be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. For example,  
25 ambient processing pressures are typical of ball mills, attritor mills and vibratory mills. Processing pressures up to about 20 psi (1.4 kg/cm<sup>2</sup>) are typical of media milling.

          Milling must be carried out under acidic conditions, at a pH of from 2-6, preferably 3-5. The preferred pH depends,  
30 e.g., on the acidity and solubility of the particular NSAID selected. Acid resistant milling equipment is highly preferred, e.g., equipment fabricated of high grade stainless steel, e.g., grade 316 SS, or equipment coated with an acid resistant coating.

35           The surface modifier, if it was not present in the premix, must be added to the dispersion after attrition in an

amount as described for the premix above. Thereafter, the dispersion can be mixed, e.g., by shaking vigorously. Optionally, the dispersion can be subjected to a sonication step, e.g., using an ultrasonic power supply. For example, 5 the dispersion can be subjected to ultrasonic energy having a frequency of 20 - 80 kHz for a time of about 1 to 120 seconds.

The relative amount of the NSAID and surface modifier can vary widely and the optimal amount of the 10 surface modifier can depend, for example, upon the particular NSAID and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the surface area of the NSAID, etc. The surface modifier preferably is present in an amount of about 0.1-10 mg per 15 square meter surface area of the NSAID. The surface modifier can be present in an amount of 0.1-90%, preferably 0.5-80%, and more preferably 1-60% by weight based on the total weight of the dry particle.

A simple screening process has been developed 20 whereby compatible surface modifiers and NSAIDs can be selected which provide stable dispersions of the desired particles. First, coarse particles of an NSAID are dispersed in a liquid in which the NSAID is essentially insoluble, e.g., water at 5% (w/v) and milled for 120 hours in a roller 25 mill under the following milling conditions:

Grinding vessel: 8 oz. (250 ml) glass jar

Available volume of grinding vessel: 250 ml

Media volume: 120 ml

Media type: 1.0 mm pre-cleaned zirconium 30 oxide beads (distributed by Zircoa, Inc.)

Milling time: 120 hours

Slurry volume: 60 ml

RPM: 92

Room Temperature pH: 4.0 (adjusted with HCl or 35 NaOH, if necessary)

The slurry is separated from the milling media by conventional means, e.g., by pouring the slurry out of the vessel, or by using a pipette. The separated slurry is then  
5 divided into aliquots and surface modifiers are added at a concentration of between 2 and 50% by weight based on the total combined weight of the NSAID and surface modifier. The dispersions are then sonicated (1 minute, 20 kHz) or vortexed using a multitubed vortexer for one minute, to disperse  
10 agglomerates and subjected to particle size analysis, e.g., by photon correlation spectroscopy and/or by examination under an optical microscope (1000 x magnification). If a stable dispersion is observed, then the process for preparing the particular NSAID surface modifier combination can be  
15 optimized in accordance with the teachings above. By stable it is meant that the dispersion exhibits no flocculation or particle agglomeration visible to the naked eye and, preferably, when viewed under the optical microscope at 1000x, at least 15 minutes, and preferably, at least two days  
20 or longer after preparation. In addition, preferred particles exhibit no flocculation or agglomeration when dispersed in 0.1 N HCl or simulated GI fluid (USP).

The resulting dispersion is stable and consists of the liquid dispersion medium and the above-described  
25 particles. The dispersion of surface modified NSAID nanoparticles can be spray coated onto sugar spheres or onto a pharmaceutical excipient in a fluid-bed spray coater by techniques well known in the art.

Pharmaceutical compositions according to this  
30 invention include the particles described above and a pharmaceutically acceptable carrier therefor. Suitable pharmaceutically acceptable carriers are well known to those skilled in the art. These include non-toxic physiologically acceptable carriers, adjuvants or vehicles for parenteral  
35 injection, for oral administration in solid or liquid form, for rectal administration, and the like. A method of

treating a mammal in accordance with this invention comprises the step of administering to the mammal in need of treatment an effective amount of the above-described pharmaceutical composition. The selected dosage level of the NSAID for treatment is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore, depends upon the particular NSAID, the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors.

It is a particularly advantageous feature that the pharmaceutical compositions of this invention exhibit reduced gastric irritation and/or more rapid onset of action as illustrated in the examples that follow.

The following examples further illustrate the invention.

#### Example 1

A nanoparticulate naproxen dispersion (Formula 1) was prepared in a roller mill as follows. A 250 ml glass jar was charged with 120 ml of 1.0 mm pre-cleaned Zirconium oxide beads (Zirbeads XR, available from Zircoa Inc., having a nominal diameter of 1.0 mm), 60 g of an aqueous slurry containing 3 g naproxen (5% by weight), purchased from Sigma, St. Louis, MO, particle size 20-30  $\mu$ m, and 1.8 g (3% by weight) Pluronic F-68, purchased from BASF Fine Chemicals, Inc., as the surface modifier. The beads were pre-cleaned by rinsing in 1 N H<sub>2</sub>SO<sub>4</sub> overnight followed by several rinses with deionized water. The batch was rolled at 92 RPM for a total of 120 hours. The dispersion was stable when a portion was added to 0.1 N HCl. The average particle size measured by photon correlation spectroscopy was 240-300 nm.

A control formulation of naproxen was prepared by adding 5% (w/v) unmilled naproxen to 3% Pluronic F-68. The suspension was vortexed and sized. The particle size range was 20-30  $\mu$ m.

The concentration of naproxen in both formulations was 50 mg/mL (w/v). Both formulations were diluted with 3% Pluronic F-68 to a dosing concentration of 10 mg/mL for oral administration.

5 Male Sprague-Dawley rats were maintained in accordance with the conditions set forth in "Guide for the Care and Use of Laboratory Animals", NIH Publication 86-23. The temperature was maintained at  $22 \pm 1^\circ\text{C}$  and the relative humidity was  $50 \pm 10\%$ , with a 12 hour light/dark cycle. Rats  
10 were provided laboratory chow and water. The rats (250-350 g) were anesthetized with a 55 mg/kg intraperitoneal injection of Nembutal (sodium pentobarbital). The external jugular veins were chronically cannulated to facilitate removal of blood samples. Prior to administration of  
15 naproxen, the rats were allowed to recover for 24 hours with water ad libitum.

The rats were anesthetized, with Metofane, orally gavaged with the above-described formulations and placed in a restraint device. Blood samples (100  $\mu\text{l}$ ) were obtained via  
20 the jugular vein at 0 (pre-administration), 5, 10, 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes following administration of naproxen and collected in heparinized tubes. Plasma (50  $\mu\text{l}$ ) was obtained immediately and placed on ice. Plasma samples (50  $\mu\text{l}$ ) were mixed with 130  $\mu\text{l}$  of  
25 acetonitrile and 20  $\mu\text{l}$  of a standard solution (20  $\mu\text{g/ml}$  indomethacin) and vortexed to precipitate protein. Samples were centrifuged and the supernatants removed, placed in vials, and analyzed by HPLC. The separation of naproxen was carried out on an analytical column (Waters Novapak C18; 15  
30 cm x 4 mm, 5 $\mu$ ).

At the end of the experiment (240 min.) the rats were euthanized by an I.V. bolus injection of Nembutal via the jugular vein. The stomachs were removed and cut along the line of greater curvature from the duodenum to the  
35 pyloric sphincter. The stomachs were then spread flat and pinned out on dissecting dishes, and washed with 0.9% NaCl.

The evaluation and counting of stomach irritations (erosion/lesion/ulcer) were conducted by a modification of arbitrary scoring systems (Cioli et al, Tox. and Appl. Pharm., 1979, 50: 283-289 and Beck et al, Arch. Toxicol., 1990; 64: 210-217) correcting for various degrees of severity as noted below. Differences in severity index have been associated with the gastropathology present on the stomach following oral administration of NSAIDs (Balaa, Am. Journ. Med. Sci., 1991, 301: 272-276 and Lanza et al; Dig. Dis. and Sci., 1990; 35:12).

Each stomach irritation was measured in length (or diameter) using a 10 mm surgical ruler. The length of the irritations ranged from 0.25 mm to 10.0 mm. Irritations less than 0.25 mm were classified as pinpoint. The irritations were categorized by color as an evaluation of severity. Irritations red in appearance were rated as mild and assigned a severity value of 1. Brown irritations were rated as moderately severe and assigned a value of 2. Irritations which appeared black were rated as the most severe and given a severity value of 3. A score for each irritation was determined by multiplying the length value and the point severity level. The sum total for all irritations on a given stomach was identified as the total irritation score.

Table 1 shows the mean values for the stomach irritations induced by naproxen in the Control formulation and Formulation 1 of this invention. As indicated by the data, the formulation of this invention exhibited a reduction in stomach irritation scores compared to the control ( $p = 0.099$ ). It was concluded that the formulation of this invention exhibits reduced gastric irritation following oral administration as compared to the control.

Table 1

	<u>Rat No.</u>	<u>Control (n=6)</u>	<u>Formulation 1 (n=8)</u>
	1	293	43
5	2	200	139
	3	133	149
	4	140	80
	5	110	129
	6	101	163
10	7		54
	8		98
	Mean	163	107
	SEM	30	16

15 Surprisingly, the formulation of this invention  
when administered orally induced a similar level of gastric  
irritation compared to the same formulation administered  
parenterally, i.e., I.V.. Thus, the formulation of this  
invention appears virtually devoid of a direct irritant  
20 effect on the stomach of a rat.

A statistical comparison of the pharmacokinetic  
plasma parameters Cmax (peak plasma concentration), Tmax  
(time to peak plasma concentration) and relative  
bioavailability (AUC<sub>(0-240 min)</sub> - from Area Under the Curve  
25 values from 0-240 minutes) for Formulation 1 of this  
invention and the control calculated by the trapezoidal  
method is set forth below.

		Mean $\pm$ SEM	
		<u>Control</u>	<u>Formulation 1</u>
5	Cmax	126 $\pm$ 4	187 $\pm$ 19
	( $\mu$ g/ml)	(n=5)	(n=6)
	Tmax	34 $\pm$ 3	24 $\pm$ 5
	(min)	(n=5)	(n=6)
10	AUC(0-240 min)	15,228 $\pm$ 994	19,062 $\pm$ 573
	( $\mu$ g $\times$ min/ml)	(n=5)	(n=3)

The data indicate that the time to peak plasma concentration were lower for the formulation of this invention compared to the control ( $p=0.15$ ) and both the relative bioavailability and peak plasma concentrations were significantly higher for the formulation of this invention compared to the control ( $p=0.03$ ) and ( $p=0.02$ ), respectively. The increase in apparent rate of absorption clearly suggests enhanced onset of action.

#### Example 2

The preparation of Example 1 was repeated except that 5% by weight polyvinylpyrrolidone was used in place of the Pluronic F-68. The average particle size was 250 nm.

Examples 3-8 illustrate the preparation of nanoparticulate ibuprofen.

#### 30 Example 3

Nanoparticulate ibuprofen was prepared in a planetary mill (Pulverisette-7, manufactured by Fritsch, GmbH) containing two 25 ml bowls. The initial charge (per bowl) included 12.5 ml of 1 mm pre-cleaned zirconium oxide beads and 6.25 ml of an aqueous slurry containing 100 mM HCl, 3% (w/v) ibuprofen, and 2% (w/v) Pluronic F-68 as the surface modifier. The ibuprofen formulation was milled for 24 hours

at 325 RPM. The resulting dispersion was stable when a portion was added to simulated gastric fluid, i.e., 2 g NaCl, 3.2 g pepsin, 7 ml HCl, and H<sub>2</sub>O to 1 liter, pH=1:2. The average particle size measured by photon correlation spectroscopy was 253 nm.

#### Example 4

Example 3 was repeated except that the initial charge included 1% Tween 20 and the milling time was 17 hours. The average particle size was 263 nm.

#### Example 5

Example 3 was repeated except that the milling time was 4 hours. The average particle size was 314 nm.

#### Example 6

Example 3 was repeated except that the surface modifier in the initial charge was 1% (w/v) of a 1:2 by weight mixture of Tween 20 and Span 20, and the milling time was 20 hours at 175 RPM. The average particle size was 294 nm.

#### Example 7

Example 3 was repeated except that the initial charge included 0.25% (w/v) tyloxapol as the surface modifier and 10 mM HCl. The charge was milled for 20 hours at 175 RPM in a refrigerated (5°C) area. The average particle size was 344 nm.

Example 8

Example 7 was repeated except that Tween 20 was used in place of the tyloxapol. The average particle size was 351 nm.

5

Examples 9-12 illustrate the preparation of nanoparticulate indomethacin.

Example 9

10 Nanoparticulate indomethacin was prepared in a roller mill as follows. A 250 ml bottle was charged with 125 ml of 1.0 mm pre-cleaned ZrO<sub>2</sub> beads, 200 gm of an aqueous slurry containing 10 gms indomethacin (5% by weight) and 2 gms Vinol 205, a polyvinylalcohol (1% by weight). A batch  
15 size of 200 gms was used to reduce air space in the bottle to minimize the formation of foam. The batch was rolled at 88.5 RPM for a total of 240 hours. The dispersion was stable in 0.1 N HCl and simulated gastric fluid as described in Example 3 above. The average particle size measured by photon  
20 correlation spectroscopy was 331 nm.

Example 10

Example 9 was repeated except that polyvinylpyrrolidone was used in place of the  
25 polyvinylalcohol. The average particle size was 216 nm.

Example 11

Example 9 was repeated except that Pluronic F-68 was used in place of the polyvinylalcohol. The average  
30 particle size was 228 nm.

Example 12

Example 9 was repeated except that Pluronic F-108 was used in place of the polyvinylalcohol. The average particle size was 235 nm.

5

The invention has been described in detail with particular reference to certain preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.

10

What is claimed is:

1. Particles consisting essentially of an NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an average particle size of less than about 400 nm.
2. The particles of claim 1 having an effective average particle size of less than 300 nm.
3. The particles of claim 1 wherein said surface modifier is present in an amount of 0.1 to 90% by weight based on the total weight of the dry particle.
4. The particles of claim 1 wherein said NSAID is selected from nabumetone, tiaramide, proquazone, bufexamac, flumizole, epirazole, tinoridine, timegadine, dapsone, aspirin, diflunisal, benorylate, fosfosal, diclofenac, alclofenac, fenclofenac, etodolac, indomethacin, sulindac, tolmetin, fentiazac, tilomisole, carprofen, fenbufen, flurbiprofen, ketoprofen, oxaprozin, suprofen, tiaprofenic acid, ibuprofen, naproxen, fenoprofen, indoprofen, piroprofen, flufenamic, mefenamic, meclofenamic, niflumic, oxyphenbutazone, phenylbutazone, apazone and feprazone, piroxicam, sudoxicam, isoxicam and tenoxicam.
5. The particles of claim 1 wherein said NSAID is selected from naproxen, indomethacin and ibuprofen.
6. The particles of claim 1 wherein said surface modifier is selected from polyvinylpyrrolidone and a block copolymer of ethylene oxide and propylene oxide.
7. Particles consisting of naproxen having a block copolymer of ethylene oxide and propylene oxide adsorbed on the surface thereof in an amount sufficient to maintain an average particle size of less than about 400 nm.
8. Particles consisting essentially of naproxen having polyvinylpyrrolidone adsorbed on the surface thereof in an amount sufficient to maintain an average particle size of less than about 400 nm.
9. A pharmaceutical composition comprising the particles of claim 1 and a pharmaceutically acceptable

carrier.

10. A method of treating a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of claim 9.

5 11. A method of reducing gastric irritation following oral administration to a mammal of a pharmaceutical composition comprising an NSAID, said method comprising administering said pharmaceutical composition in the form of particles consisting essentially of said NSAID having a  
10 surface modifier adsorbed thereon in an amount sufficient to maintain an average particle size of less than about 400 nm.

12. A method of hastening onset of action following administration to a mammal of a pharmaceutical composition comprising an NSAID, said method comprising administering  
15 said pharmaceutical composition in the form of particles consisting essentially of said NSAID having a surface modifier adsorbed thereon in an amount sufficient to maintain an average particle size of less than about 400 nm.

13. A method of hastening onset of action following  
20 administration to a mammal of a pharmaceutical composition, said method comprising administering said pharmaceutical composition in the form of particles consisting essentially of a drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an  
25 average particle size of less than about 400 nm.

14. A method of preparing the particles of claim 1 comprising the steps of dispersing an NSAID in a liquid dispersion medium and wet grinding said NSAID in the presence of rigid grinding media to an effective average particle size  
30 of less than about 400 nm, wherein the pH of said medium is maintained within the range of from 2 to 6 during said wet grinding.

15. The method of claim 14 wherein a surface modifier is present during said wet grinding.

35 16. The method of claim 14 further including the step of contacting said NSAID with a surface modifier after wet

grinding by mixing said surface modifier with said dispersion medium.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/05082

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K9/14		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0 371 431 (VECTORPHARMA INTERNATIONAL) 6 June 1990	1-6,8-13
Y	see page 3, line 19 - line 24 see page 3, line 38 see page 3, line 45 - line 57 see page 4, line 25 - line 28 ---	7,14,15
X	WO,A,9 203 380 (THE UNIVERSITY OF ROCHESTER) 5 March 1992 see page 5, line 30 - line 33 see page 6, line 23 - line 34 see page 12, line 11 - line 31 ---	1-4,6,9
-/--		
<sup>10</sup> Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03 AUGUST 1993	18. 08. 93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	VENTURA AMAT A.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0 169 618 (STERILIZATION TECHNICAL SERVICES INC.) 29 January 1986 see claims 1,8,10,18 ----	1-4,6,9
X	WO,A,9 015 593 (YTKEMISKA INSTITUTET) 27 December 1990 see claim 1 see page 4, line 20 - page 6, line 10 see page 7, line 16 - page 8, line 35 ----	1-4,6,9
P,X	EP,A,0 499 299 (STERLING WINTHROP INC.) 19 August 1992 see the whole document ----	1-16
Y	WO,A,9 200 725 (FARCON AG) 23 January 1992 see claims 1,4,9,10 ----	7
Y	WO,A,9 106 292 (DANOCEMO) 16 May 1991 see claims 1,8,9,10 see page 4, line 35 - page 5, line 9 -----	14,15

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/ 05082

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**REMARK: Although claims 10-13 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9305082  
SA 75273

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03/08/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0371431	06-06-90	CA-A-	2004064	28-05-90
		JP-A-	2184621	19-07-90
WO-A-9203380	05-03-92	AU-B-	579166	17-11-88
		AU-A-	4501285	22-01-87
		CA-A-	1282405	02-04-91
		EP-A, B	0169618	29-01-86
		EP-A-	0544657	09-06-93
		JP-A-	62027032	05-02-87
		PT-A-	80494	22-11-85
		US-A-	4997454	05-03-91
		US-A-	4826689	02-05-89
EP-A-0169618	29-01-86	AU-B-	579166	17-11-88
		AU-A-	4501285	22-01-87
		CA-A-	1282405	02-04-91
		EP-A-	0544657	09-06-93
		JP-A-	62027032	05-02-87
		PT-A-	80494	22-11-85
		WO-A-	9203380	05-03-92
		US-A-	4997454	05-03-91
		US-A-	4826689	02-05-89
WO-A-9015593	27-12-90	SE-B-	464743	10-06-91
		AU-A-	5937590	08-01-91
		SE-A-	8902257	22-12-90
EP-A-0499299	19-08-92	US-A-	5145684	08-09-92
		AU-A-	1014592	30-07-92
		AU-A-	1014792	30-07-92
		EP-A-	0498482	12-08-92
		JP-A-	4317053	09-11-92
		JP-A-	4295420	20-10-92
WO-A-9200725	23-01-92	AU-A-	8093591	04-02-92
		EP-A-	0491897	01-07-92
WO-A-9106292	16-05-91	AU-A-	6632490	31-05-91
		EP-A-	0498824	19-08-92